126 related articles for article (PubMed ID: 8270442)
1. RTOG #89-06: a phase I study to evaluate intraoperative radiation therapy and the hypoxic cell sensitizer etanidazole in locally advanced malignancies.
Halberg FE; Cosmatis D; Gunderson LL; Noyes RD; Hanks GR; Buswell L; Nagorney DM; Coleman CN
Int J Radiat Oncol Biol Phys; 1994 Jan; 28(1):201-6. PubMed ID: 8270442
[TBL] [Abstract][Full Text] [Related]
2. Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support.
Elias AD; Wheeler C; Ayash LJ; Schwartz G; Ibrahim J; Mills L; McCauley M; Coleman N; Warren D; Schnipper L; Antman KH; Teicher BA; Frei E
Clin Cancer Res; 1998 Jun; 4(6):1443-9. PubMed ID: 9626461
[TBL] [Abstract][Full Text] [Related]
3. Radiosensitization by a new potent nucleoside analog: 1-(1',3',4'-trihydroxy-2'-butoxy)methyl-2-nitroimidazole(RP-343).
Murayama C; Suzuki A; Sato C; Tanabe Y; Shoji T; Miyata Y; Nishio A; Suzuki T; Sakaguchi M; Mori T
Int J Radiat Oncol Biol Phys; 1993 Jun; 26(3):433-43. PubMed ID: 8514541
[TBL] [Abstract][Full Text] [Related]
4. Results of a phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer (RTOG Protocol 90-20).
Lawton CA; Coleman CN; Buzydlowski JW; Forman JD; Marcial VA; DelRowe JD; Rotman M
Int J Radiat Oncol Biol Phys; 1996 Oct; 36(3):673-80. PubMed ID: 8948352
[TBL] [Abstract][Full Text] [Related]
5. Intervention with the hypoxic tumor cell sensitizer etanidazole in the combined modality treatment of limited stage small-cell lung cancer. A one-institution study.
Urtasun RC; Palmer M; Kinney B; Belch A; Hewitt J; Hanson J
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(2):337-42. PubMed ID: 9457818
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer.
Brown JM; Diehn M; Loo BW
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):323-7. PubMed ID: 20832663
[TBL] [Abstract][Full Text] [Related]
7. A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma.
Marcus KJ; Dutton SC; Barnes P; Coleman CN; Pomeroy SL; Goumnerova L; Billett AL; Kieran M; Tarbell NJ
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1182-5. PubMed ID: 12654425
[TBL] [Abstract][Full Text] [Related]
8. Final report of the phase I trial of continuous infusion etanidazole (SR 2508): a Radiation Therapy Oncology Group study.
Coleman CN; Noll L; Riese N; Buswell L; Howes AE; Loeffler JS; Alexander E; Wen P; Harris JR; Kramer RA
Int J Radiat Oncol Biol Phys; 1992; 22(3):577-80. PubMed ID: 1531217
[TBL] [Abstract][Full Text] [Related]
9. A phase I-B trial of the radiosensitizer: etanidazole (SR-2508) with radiosurgery for the treatment of recurrent previously irradiated primary brain tumors or brain metastases (RTOG Study 95-02).
Drzymala RE; Wasserman TH; Won M; Shaw E; Cmelak AJ; Loeffler J; Souhami L;
Radiother Oncol; 2008 Apr; 87(1):89-92. PubMed ID: 18342381
[TBL] [Abstract][Full Text] [Related]
10. Pilot study of local hyperthermia, radiation therapy, etanidazole, and cisplatin for advanced superficial tumours.
Bornstein BA; Herman TS; Hansen JL; Buswell L; Zouranjian PS; Fraser SM; Teicher BA; Svensson GK; Coleman CN
Int J Hyperthermia; 1995; 11(4):489-99. PubMed ID: 7594803
[TBL] [Abstract][Full Text] [Related]
11. The multi-dose clinical tolerance and pharmacokinetics of the combined radiosensitizers, Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
Newman HF; Ward R; Workman P; Bleehen NM
Int J Radiat Oncol Biol Phys; 1988 Nov; 15(5):1073-83. PubMed ID: 2972667
[TBL] [Abstract][Full Text] [Related]
12. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas.
Lee DJ; Cosmatos D; Marcial VA; Fu KK; Rotman M; Cooper JS; Ortiz HG; Beitler JJ; Abrams RA; Curran WJ
Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):567-76. PubMed ID: 7790241
[TBL] [Abstract][Full Text] [Related]
13. Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) Radiation Therapy Oncology Group 83-03.
Coleman CN; Wasserman TH; Urtasun RC; Halsey J; Noll L; Hancock S; Phillips TL
Int J Radiat Oncol Biol Phys; 1990 Feb; 18(2):389-93. PubMed ID: 2154420
[TBL] [Abstract][Full Text] [Related]
14. Initial results of a phase I trial of continuous infusion SR 2508 (etanidazole): a radiation therapy oncology group study.
Coleman CN; Noll L; Howes AE; Harris JR; Zakar J; Kramer RA
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1085-7. PubMed ID: 2522919
[TBL] [Abstract][Full Text] [Related]
15. Phase I pharmacokinetic study of the hypoxic cell sensitizer etanidazole with carboplatin and cyclophosphamide in the treatment of advanced ovarian cancer.
Shulman LN; Buswell L; Goodman H; Muto M; Berkowitz R; Teicher B; Kusumoto T; Hurwitz SJ; Kalish LA; Coleman CN
Int J Radiat Oncol Biol Phys; 1994 Jun; 29(3):545-8. PubMed ID: 8005814
[TBL] [Abstract][Full Text] [Related]
16. Use of the hypoxic cell sensitizer etanidazole (SR-2508) with intravenous melphalan and prednisone in the treatment of multiple myeloma: a pharmacokinetic study.
Shulman LN; Buswell L; Kalish LA; Coleman CN
Int J Radiat Oncol Biol Phys; 1994 Jun; 29(3):541-3. PubMed ID: 8005813
[TBL] [Abstract][Full Text] [Related]
17. Hypoxic cell sensitization: low-dose intrinsic radiosensitivity is predictive for etanidazole efficacy in a panel of human tumour cell lines.
Wouters BG; Sy AM; Skarsgard LD
Int J Radiat Biol; 1996 Dec; 70(6):719-33. PubMed ID: 8980670
[TBL] [Abstract][Full Text] [Related]
18. Local hyperthermia, radiation therapy, and chemotherapy in patients with local-regional recurrence of breast carcinoma.
Bornstein BA; Zouranjian PS; Hansen JL; Fraser SM; Gelwan LA; Teicher BA; Svensson GK
Int J Radiat Oncol Biol Phys; 1993 Jan; 25(1):79-85. PubMed ID: 7677990
[TBL] [Abstract][Full Text] [Related]
19. Combined-modality therapy of esophageal cancer with radiotherapy, etanidazole, and cisplatin-fluorouracil, with or without surgery: neurotoxicity, other toxicities and outcome.
Buswell L; Recht A; Clark J; Ravikumar T; Busse PM; Coleman CN
Int J Radiat Oncol Biol Phys; 1994 Jun; 29(3):535-40. PubMed ID: 8005812
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic monitoring and dose modification of etanidazole in the RTOG 85-27 phase III head and neck trial.
Riese NE; Buswell L; Noll L; Pajak TF; Stetz J; Lee DJ; Coleman CN
Int J Radiat Oncol Biol Phys; 1997 Nov; 39(4):855-8. PubMed ID: 9369134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
